Sara Gibbons

2.5k total citations · 1 hit paper
34 papers, 1.8k citations indexed

About

Sara Gibbons is a scholar working on Infectious Diseases, Pediatrics, Perinatology and Child Health and Virology. According to data from OpenAlex, Sara Gibbons has authored 34 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Infectious Diseases, 11 papers in Pediatrics, Perinatology and Child Health and 8 papers in Virology. Recurrent topics in Sara Gibbons's work include HIV/AIDS drug development and treatment (23 papers), HIV/AIDS Research and Interventions (11 papers) and Pharmacological Effects and Toxicity Studies (11 papers). Sara Gibbons is often cited by papers focused on HIV/AIDS drug development and treatment (23 papers), HIV/AIDS Research and Interventions (11 papers) and Pharmacological Effects and Toxicity Studies (11 papers). Sara Gibbons collaborates with scholars based in United Kingdom, Switzerland and United States. Sara Gibbons's co-authors include David Back, Saye Khoo, Michael Barry, Fiona Mulcahy, Catia Marzolini, Concepta Merry, Fiona Marra, Alison Boyle, David M. Burger and Andrew Owen and has published in prestigious journals such as PLoS ONE, Clinical Infectious Diseases and Clinical Pharmacology & Therapeutics.

In The Last Decade

Sara Gibbons

34 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Recommendations for the Management of Drug–Drug Interactions Between the COVID‐19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications

2022 162 citations Catia Marzolini, Fiona Marra et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sara Gibbons United Kingdom	22	1.3k	589	416	368	332	34	1.8k
Anne‐Marie Taburet France	26	1.5k 1.1×	818 1.4×	295 0.7×	271 0.7×	406 1.2×	74	2.1k
Julie Borland United States	26	1.3k 1.0×	759 1.3×	304 0.7×	209 0.6×	339 1.0×	52	2.0k
John Tjia United Kingdom	17	725 0.6×	452 0.8×	236 0.6×	220 0.6×	177 0.5×	23	1.3k
Naser L. Rezk United States	23	1.1k 0.8×	669 1.1×	208 0.5×	133 0.4×	347 1.0×	37	1.6k
Ivy Song United States	23	1.7k 1.3×	1.1k 1.9×	356 0.9×	295 0.8×	487 1.5×	52	2.1k
Rolf P. G. van Heeswijk Netherlands	24	1.9k 1.5×	750 1.3×	230 0.6×	202 0.5×	846 2.5×	41	2.3k
Joseph M. Custodio United States	18	1.4k 1.0×	874 1.5×	207 0.5×	556 1.5×	234 0.7×	40	2.0k
Gabriela Bleiber Switzerland	19	841 0.6×	830 1.4×	241 0.6×	163 0.4×	244 0.7×	24	1.5k
Anita Mathias United States	27	1.4k 1.1×	389 0.7×	448 1.1×	236 0.6×	708 2.1×	65	2.6k
Caroline Solas France	23	920 0.7×	430 0.7×	162 0.4×	171 0.5×	258 0.8×	94	1.5k

Countries citing papers authored by Sara Gibbons

Since Specialization

Citations

This map shows the geographic impact of Sara Gibbons's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sara Gibbons with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sara Gibbons more than expected).

Fields of papers citing papers by Sara Gibbons

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sara Gibbons. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sara Gibbons. The network helps show where Sara Gibbons may publish in the future.

Co-authorship network of co-authors of Sara Gibbons

This figure shows the co-authorship network connecting the top 25 collaborators of Sara Gibbons. A scholar is included among the top collaborators of Sara Gibbons based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sara Gibbons. Sara Gibbons is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Marzolini, Catia, et al.. (2024). Drug-drug interactions potential with the HIV-1 capsid inhibitor lenacapavir. Expert Opinion on Drug Metabolism & Toxicology. 21(2). 161–172. 2 indexed citations

Pham, Thao, Catia Marzolini, Sara Gibbons, et al.. (2024). DeepARV: ensemble deep learning to predict drug-drug interaction of clinical relevance with antiretroviral therapy. npj Systems Biology and Applications. 10(1). 48–48. 12 indexed citations

Costa, Juliana de Oliveira, et al.. (2022). Potential drug–drug interactions due to concomitant medicine use among people living with HIV on antiretroviral therapy in Australia. British Journal of Clinical Pharmacology. 89(5). 1541–1553. 5 indexed citations

Hodge, Daryl, David Back, Sara Gibbons, Saye Khoo, & Catia Marzolini. (2021). Pharmacokinetics and Drug–Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine. Clinical Pharmacokinetics. 60(7). 835–853. 71 indexed citations

Marzolini, Catia, Sara Gibbons, Joep J. van Oosterhout, & Saye Khoo. (2021). Drug–Drug Interaction Potential with Once-Weekly Isoniazid/Rifapentine (3HP) for the Treatment of Latent Tuberculosis Infection. Clinical Pharmacokinetics. 61(3). 339–346. 1 indexed citations

Marra, Fiona, Elise J. Smolders, Omar El‐Sherif, et al.. (2020). Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment. Drugs in R&D. 21(1). 9–27. 39 indexed citations

Marzolini, Catia, Sara Gibbons, Saye Khoo, & David Back. (2016). Cobicistat versus ritonavir boosting and differences in the drug–drug interaction profiles with co-medications. Journal of Antimicrobial Chemotherapy. 71(7). 1755–1758. 94 indexed citations

Cottle, Lucy E., et al.. (2010). Recognition of Risk for Clinically Significant Drug Interactions among HIV‐Infected Patients Receiving Antiretroviral Therapy. Clinical Infectious Diseases. 50(10). 1419–1421. 70 indexed citations

Hartkoorn, Ruben C., Neill J. Liptrott, Deirdre Egan, et al.. (2010). HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenetics and Genomics. 20(2). 112–120. 138 indexed citations

10.

Lambert, John S., Valerie Jackson, Sara Gibbons, et al.. (2010). Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy. HIV Medicine. 12(3). 166–173. 31 indexed citations

11.

Siccardi, Marco, Antonio D’Avolio, Lorena Baietto, et al.. (2008). Association of a Single‐Nucleotide Polymorphism in the Pregnane X Receptor (PXR63396C→T) with Reduced Concentrations of Unboosted Atazanavir. Clinical Infectious Diseases. 47(9). 1222–1225. 60 indexed citations

12.

Khoo, Saye, Mark Dalton, Alec Bonington, et al.. (2006). Pharmacologic Optimization of Protease Inhibitors and Nonnucleoside Reverse Transcriptase Inhibitors (POPIN)-A Randomized Controlled Trial of Therapeutic Drug Monitoring and Adherence Support. JAIDS Journal of Acquired Immune Deficiency Syndromes. 41(4). 461–467. 45 indexed citations

13.

Back, David, Sara Gibbons, & Saye Khoo. (2006). An Update on Therapeutic Drug Monitoring for Antiretroviral Drugs. Therapeutic Drug Monitoring. 28(3). 468–473. 64 indexed citations

14.

Back, David, Sara Gibbons, & Saye Khoo. (2003). Pharmacokinetic Drug Interactions with Nevirapine. JAIDS Journal of Acquired Immune Deficiency Syndromes. 34. S8–S14. 37 indexed citations

15.

Gibbons, Sara & Mabayoje A. Oriowo. (2001). Antihypertensive effect of an aqueous extract of Zygophyllum coccineum L. in rats. Phytotherapy Research. 15(5). 452–455. 17 indexed citations

16.

Barry, Michael, Fiona Mulcahy, Concepta Merry, Sara Gibbons, & David Back. (1999). Pharmacokinetics and Potential Interactions Amongst Antiretroviral Agents Used To Treat Patients with HIV Infection. Clinical Pharmacokinetics. 36(4). 289–304. 224 indexed citations

17.

Merry, Catherine L.R., F Mulcahy, Michael Barry, Sara Gibbons, & David Back. (1997). Saquinavir interaction with midazolam: pharmacokinetic considerations when prescribing protease inhibitors for patients with HIV disease.. PubMed. 11(2). 268–9. 25 indexed citations

18.

Barry, Michael, Sara Gibbons, David Back, & Fiona Mulcahy. (1997). Protease Inhibitors in Patients with HIV Disease. Clinical Pharmacokinetics. 32(3). 194–209. 216 indexed citations

19.

Grevel, Joachim, Kimberly L. Napoli, Sara Gibbons, & B D Kahan. (1990). Area-Under-the-Curve Monitoring of Cyclosporine Therapy. Therapeutic Drug Monitoring. 12(1). 8–15. 12 indexed citations

20.

Gibbons, Sara, et al.. (1988). Comparison and correlation of assays for monitoring cyclosporine drug levels in renal transplant recipients.. PubMed. 20(2 Suppl 2). 339–44. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact